Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared a post on LinkedIn:
”In preparation for my upcoming Grand Rounds presentation, I’ve put together these slides translating the recent COBRRA trial (NEJM 2026) titled:
‘Settling the DOAC Debate in Acute VTE’.
For years, major clinical guidelines haven’t recommended one DOAC over another due to a lack of head-to-head randomized trials.
Here are the most important concepts and the clinical shift this trial brings to our practice:
- Identical Efficacy: Both Apixaban and Rivaroxaban demonstrated an identical ~1% rate of recurrent VTE.
- Superior Safety: Apixaban cut the risk of clinically relevant bleeding by more than half and drove an 84% reduction in major bleeding.
- The Dosing Hypothesis: Why the difference? The bleeding divergence explodes in the first 3 weeks.
Rivaroxaban requires a high-dose induction phase that is three times longer than Apixaban (21 days vs. 7 days).
I am sharing the presentation here. Please feel free to use and adapt these slides for your own reference, clinical discussions, or teaching.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause